Abstract

Small interfering RNAs (siRNAs) have been proven as promising therapeutics for treating brain diseases owing to their high specificity for pathogenic targets, their relatively low dose requirement for therapeutic effect, and the simplicity of the drug development process.

Nanotechnology can enable siRNA to overcome issues relating to during circulation, brain entry, and diseased tissue/cell targeting by engineering siRNA and related delivery carriers into nanoparticles, together with chemical and biological modifications.

A biomimetic camouflage strategy, glycemia-controlled GLUT1 receptor-mediated transport, and tight junction opening agents can be potentially employed to help siRNA nanomedicine pass the BBB for more effective brain disease therapy.